Clinical characteristics, antimicrobial susceptibilities, and outcomes of patients with Chr+yseobacterium indologenes bacteremia in an intensive care unit

Deng Wei Chou, Shu Ling Wu, Chao Tai Lee, Fan Ting Tai, Wen Liang Yu

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Ten patients with intensive care unit (ICU)-acquired Chryseobacterium indologenes bacteremia between January 2004 and December 2008 were studied. The primary site of infection was unknown for 80z of the cases. The known primary sites of infection were empyema (10z) and catheter-related bacteremia (10z). Eight patients (80z) had polymicrobial bacteremia, spent more than 21 days in the ICU, and received more than 14 days of broad-spectrum antibiotic therapy prior to the onset of C. indologenes bacteremia. All isolates were 100z susceptible to minocycline and trimethoprim/sulfamethoxazole. Vancomycin, imipenem, piperacillin/tazobactam, ciprofloxacin, and levofloxacin exhibited 0z, 10z, 20z, 30z, and 30z, respectively, susceptibility against this pathogen. All isolates were 100z resistant to ceftazidime, cefepime, meropenem, piperacillin, and amikacin. The 14-day mortality rate was 40z. Our findings suggest that this pathogen should be included among the causes of ICU-acquired bacteremia, especially in patients with a prolonged stay in an ICU or who had received long-term broad-spectrum antibiotic therapy. Extended-spectrum penicillins, third- and fourth-generation cephalosporins, and quinolones had very little or no effect against this pathogen. Therefore, choosing an appropriate antibiotic therapy for this pathogen is very difficult.

Original languageEnglish
Pages (from-to)520-524
Number of pages5
JournalJapanese Journal of Infectious Diseases
Volume64
Issue number6
Publication statusPublished - 2011

Fingerprint

Bacteremia
Intensive Care Units
meropenem
Anti-Bacterial Agents
Chryseobacterium
Levofloxacin
Minocycline
Piperacillin
Empyema
Ceftazidime
Amikacin
Imipenem
Quinolones
Sulfamethoxazole Drug Combination Trimethoprim
Cephalosporins
Vancomycin
Ciprofloxacin
Infection
Penicillins
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Clinical characteristics, antimicrobial susceptibilities, and outcomes of patients with Chr+yseobacterium indologenes bacteremia in an intensive care unit. / Chou, Deng Wei; Wu, Shu Ling; Lee, Chao Tai; Tai, Fan Ting; Yu, Wen Liang.

In: Japanese Journal of Infectious Diseases, Vol. 64, No. 6, 2011, p. 520-524.

Research output: Contribution to journalArticle

@article{5439c93568604e2b8aaeff90cf18330d,
title = "Clinical characteristics, antimicrobial susceptibilities, and outcomes of patients with Chr+yseobacterium indologenes bacteremia in an intensive care unit",
abstract = "Ten patients with intensive care unit (ICU)-acquired Chryseobacterium indologenes bacteremia between January 2004 and December 2008 were studied. The primary site of infection was unknown for 80z of the cases. The known primary sites of infection were empyema (10z) and catheter-related bacteremia (10z). Eight patients (80z) had polymicrobial bacteremia, spent more than 21 days in the ICU, and received more than 14 days of broad-spectrum antibiotic therapy prior to the onset of C. indologenes bacteremia. All isolates were 100z susceptible to minocycline and trimethoprim/sulfamethoxazole. Vancomycin, imipenem, piperacillin/tazobactam, ciprofloxacin, and levofloxacin exhibited 0z, 10z, 20z, 30z, and 30z, respectively, susceptibility against this pathogen. All isolates were 100z resistant to ceftazidime, cefepime, meropenem, piperacillin, and amikacin. The 14-day mortality rate was 40z. Our findings suggest that this pathogen should be included among the causes of ICU-acquired bacteremia, especially in patients with a prolonged stay in an ICU or who had received long-term broad-spectrum antibiotic therapy. Extended-spectrum penicillins, third- and fourth-generation cephalosporins, and quinolones had very little or no effect against this pathogen. Therefore, choosing an appropriate antibiotic therapy for this pathogen is very difficult.",
author = "Chou, {Deng Wei} and Wu, {Shu Ling} and Lee, {Chao Tai} and Tai, {Fan Ting} and Yu, {Wen Liang}",
year = "2011",
language = "English",
volume = "64",
pages = "520--524",
journal = "Japanese Journal of Infectious Diseases",
issn = "1344-6304",
publisher = "National Institute of Health",
number = "6",

}

TY - JOUR

T1 - Clinical characteristics, antimicrobial susceptibilities, and outcomes of patients with Chr+yseobacterium indologenes bacteremia in an intensive care unit

AU - Chou, Deng Wei

AU - Wu, Shu Ling

AU - Lee, Chao Tai

AU - Tai, Fan Ting

AU - Yu, Wen Liang

PY - 2011

Y1 - 2011

N2 - Ten patients with intensive care unit (ICU)-acquired Chryseobacterium indologenes bacteremia between January 2004 and December 2008 were studied. The primary site of infection was unknown for 80z of the cases. The known primary sites of infection were empyema (10z) and catheter-related bacteremia (10z). Eight patients (80z) had polymicrobial bacteremia, spent more than 21 days in the ICU, and received more than 14 days of broad-spectrum antibiotic therapy prior to the onset of C. indologenes bacteremia. All isolates were 100z susceptible to minocycline and trimethoprim/sulfamethoxazole. Vancomycin, imipenem, piperacillin/tazobactam, ciprofloxacin, and levofloxacin exhibited 0z, 10z, 20z, 30z, and 30z, respectively, susceptibility against this pathogen. All isolates were 100z resistant to ceftazidime, cefepime, meropenem, piperacillin, and amikacin. The 14-day mortality rate was 40z. Our findings suggest that this pathogen should be included among the causes of ICU-acquired bacteremia, especially in patients with a prolonged stay in an ICU or who had received long-term broad-spectrum antibiotic therapy. Extended-spectrum penicillins, third- and fourth-generation cephalosporins, and quinolones had very little or no effect against this pathogen. Therefore, choosing an appropriate antibiotic therapy for this pathogen is very difficult.

AB - Ten patients with intensive care unit (ICU)-acquired Chryseobacterium indologenes bacteremia between January 2004 and December 2008 were studied. The primary site of infection was unknown for 80z of the cases. The known primary sites of infection were empyema (10z) and catheter-related bacteremia (10z). Eight patients (80z) had polymicrobial bacteremia, spent more than 21 days in the ICU, and received more than 14 days of broad-spectrum antibiotic therapy prior to the onset of C. indologenes bacteremia. All isolates were 100z susceptible to minocycline and trimethoprim/sulfamethoxazole. Vancomycin, imipenem, piperacillin/tazobactam, ciprofloxacin, and levofloxacin exhibited 0z, 10z, 20z, 30z, and 30z, respectively, susceptibility against this pathogen. All isolates were 100z resistant to ceftazidime, cefepime, meropenem, piperacillin, and amikacin. The 14-day mortality rate was 40z. Our findings suggest that this pathogen should be included among the causes of ICU-acquired bacteremia, especially in patients with a prolonged stay in an ICU or who had received long-term broad-spectrum antibiotic therapy. Extended-spectrum penicillins, third- and fourth-generation cephalosporins, and quinolones had very little or no effect against this pathogen. Therefore, choosing an appropriate antibiotic therapy for this pathogen is very difficult.

UR - http://www.scopus.com/inward/record.url?scp=82355161189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82355161189&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 520

EP - 524

JO - Japanese Journal of Infectious Diseases

JF - Japanese Journal of Infectious Diseases

SN - 1344-6304

IS - 6

ER -